Anticoagulation and platelet antiaggregation therapy in stroke prevention

Current Opinion in Neurology

Volumn 18, Issue 1, 2005, Pages 53-57

  Chong, Ji Y ^a   Mohr, Jay P ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Anticoagulation; Antiplatelet therapy; Clinical trials; Secondary stroke prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; DIPYRIDAMOLE; STATINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG CHOICE; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; OUTCOMES RESEARCH; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT PLANNING;

EID: 13944263178     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200502000-00011     Document Type: Review

References (19)

1. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342:1255-1262.
2. Chimowitz MI, Kokkinos J, Strong J, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology 1995; 45:1488-1493.
3. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. Ann Intern Med 2003; 138:831-838. Full review of the algorithm for use of oral anticoagulants for stroke risk in a setting of atrial fibrillation.
4. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342:1255-1262.
5. SPORTIF Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362:1691-1698. An alternative to warfarin, but its use in the USA recently blocked by the FDA.
6. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992; 117:461-465.
7. Mohr JP. Cryptogenic stroke [editorial]. New Eng J Med 1988; 318:1197-1198.
8. Mas J, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345:1740-1746.
9. Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale. Circulation 2002; 105:262-2631.
10. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345:1444-1451.
11. Chimowitz MI, Lynn M, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial: final results. Presented at the American Heart Association International Stroke Conference, 2004 (Abstract). Stroke 2004; 35:235. No difference between aspirin (1300 mg/day) and warfarin (INR 2-3) in prevention of recurrent stroke over a 2-year period. Higher rates of hemorrhage for the warfarin group. Full publication pending.
12. Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. The Cochrane Library 2004. Cochrane review
13. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584. No relationship found between antiphospholipid-positive status and recurrent ischemic stroke in a 2-year period.
14. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
15. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289:2947-2957.
16. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
17. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
18. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004; 364:331-337. Comparable rates of recurrent stroke with aspirin + clopidogrel and clopidogrel alone, and statistically significant higher rate of hemorrhage with the combined therapy.
19. Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neural Sci 1996; 143:1-13.